مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

307
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

159
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

ALTERATION OF PANEL-REACTIVE ANTIBODIES FOLLOWING TREATMENT WITH EITHER ATORVASTATIN OR LOW-DOSE MYCOPHENOLATE MOFETIL IN SENSITIZED HEMODIALYSIS PATIENTS

Pages

  342-346

Abstract

 Introduction: Both ATORVASTATIN and MYCOPHENOLATE MOFETIL (MMF) have been used for panel reactive antibodies (PRA) reduction in transplant candidates. The purpose of this study was to compare the effect of low-dose MMF and ATORVASTATIN on PRA in sensitized HEMODIALYSIS patients waiting for KIDNEY TRANSPLANTATION.Materials and Methods: A total of 40 adult patients with end-stage renal disease who were highly sensitized to human leukocyte antigens (PRA>40%) were enrolled and randomly assigned into ATORVASTATIN or low-dose MMF groups. All of the patients received the treatments for 2 months. The PRA status was determined at the end of the 1st and 2nd month.Results: Forty percent of the patients in the ATORVASTATIN group compared with 5% in the low-dose MMF group showed complete response, defined as a minimum 50% reduction in PRA (P=0.02).Reduction of PRA in the ATORVASTATIN group was significantly higher than that in the low-dose MMF group (P=0.01). No major infectious or other complications occurred in our patients.Conclusions: ATORVASTATIN has a significant effect on lowering of PRA in sensitized HEMODIALYSIS patients waiting for KIDNEY TRANSPLANTATION. In addition, a short course of low-dose MMF is safe in ESRD patients, however, it has no effect on reduction of PRA.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    GHORBANI, ALI, SHAHBAZIAN, HESHMATOLLAH, EHSANPOUR, ALI, & AREF, ASIEH. (2011). ALTERATION OF PANEL-REACTIVE ANTIBODIES FOLLOWING TREATMENT WITH EITHER ATORVASTATIN OR LOW-DOSE MYCOPHENOLATE MOFETIL IN SENSITIZED HEMODIALYSIS PATIENTS. IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD), 5(5), 342-346. SID. https://sid.ir/paper/309342/en

    Vancouver: Copy

    GHORBANI ALI, SHAHBAZIAN HESHMATOLLAH, EHSANPOUR ALI, AREF ASIEH. ALTERATION OF PANEL-REACTIVE ANTIBODIES FOLLOWING TREATMENT WITH EITHER ATORVASTATIN OR LOW-DOSE MYCOPHENOLATE MOFETIL IN SENSITIZED HEMODIALYSIS PATIENTS. IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD)[Internet]. 2011;5(5):342-346. Available from: https://sid.ir/paper/309342/en

    IEEE: Copy

    ALI GHORBANI, HESHMATOLLAH SHAHBAZIAN, ALI EHSANPOUR, and ASIEH AREF, “ALTERATION OF PANEL-REACTIVE ANTIBODIES FOLLOWING TREATMENT WITH EITHER ATORVASTATIN OR LOW-DOSE MYCOPHENOLATE MOFETIL IN SENSITIZED HEMODIALYSIS PATIENTS,” IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD), vol. 5, no. 5, pp. 342–346, 2011, [Online]. Available: https://sid.ir/paper/309342/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button